China NRDL 2022 Update – Spotlight on Oncology (Part 2 of 3)
Recent updates to China’s NRDL have a big impact on oncology therapies. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what that means for multinationals in this free brief (part 2 of 3).
